---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088239"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:06:51.709222+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio plans spin-off of biopharma as First Tracks (TRAX); Q4 net income $49.6M

## Summary
- Spin-off of biopharma portfolio into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially late April.
- Q4 2025 net income $49.6M ($1.79 EPS); full year net loss $13.2M ($0.46 loss per share).
- Collaboration revenue Q4 $108.2M (up from $43.1M); Jemperli royalties $32.7M (+89% YoY).
- GSK Jemperli Q4 sales $343M, annualized ~$1.4B; peak sales guidance >$2.7B; expect >$390M annual royalties.
- Cash $311.6M at year-end; stock repurchased 3.44M shares for $68.6M under program expiring March 31, 2026.

## SEC filing metadata
- accession: 0001193125-26-088239
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/0001193125-26-088239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088239
- JSON: https://secwatch.observer/filing/0001193125-26-088239.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.